Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Immunogenicity of V175 and V175A in Healthy Adults
NCT07855510Phase 1Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Primary completion
- Aug 2028
01
Overview
Phase 1, randomised, double-blind trial of V175 and V175A in lower respiratory tract infection (LRTI) (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Immediate Reactions After Vaccination at 30 minutes, Percentage of Participants With a Solicited Injection-Site Adverse Event at 7 days and 5 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
V175V175A
03
Conditions
lower respiratory tract infection (LRTI)
Beyond the preview
Go deeper on NCT07855510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07855510.